Manabu Akazawa

25PUBLICATIONS
27CO-AUTHORS
Nephrology and urologyRespiratory diseasesPharmacogenomicsPharmaceutical delivery technologiesPacific Peoples youth and family
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jun 22, 2026
Do the treatment selection factors emphasized in clinical guidelines-Chronic kidney disease, cardiovascular disease, and heart failure-contribute to the risk of urinary tract infections during the administration of sodium-glucose cotransporter-2 inhibitors?

|Mar 01, 2026
Risk factors of serious infections in patients with large-vessel vasculitis after the approval of tocilizumab in 2017: a retrospective nested case-control study using the Japanese health insurance database.

Sari Horiuchi, Yukumitsu Kudo, Kotaro Kawano

|Nov 28, 2025
Time trends in the prescription of sodium-glucose co-transporter-2 inhibitors based on a claims database in Japan from 2014 to 2022: expanded use in older adults, those with comorbidities, and those potentially initiating diabetes treatment.

Takuma Koinuma, Manato Yoshida, Manabu Akazawa

|Aug 06, 2025
Evaluating the Potential of Prevalent New User Design as an Alternative When New User Design is Impractical.

Takuma Koinuma, Manabu Akazawa

|Apr 29, 2024
Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses.

Yusuke Okada, Ken Inada, Manabu Akazawa

|Mar 13, 2024
Factors Related to Treatment Non-Adherence Among Caregivers of Pediatric and Adolescent Growth Hormone Deficiency Patients in Japan.

Manabu Akazawa, Takahiro Sato, Nozomi Ebata

Pageof 5

Frequent Collaborators

2 joint publications

Nozomi Ebata

2 joint publications

Shutaro Murakami

2 joint publications

Ryosuke Nishi

2 joint publications

Hitoshi Honda